Table 1

Clinical trials of drugs targeting neutrophils

Drug	Phase	Disease	Trial identifier	Study status
CXCR2/IL-8 antagonists
AZD5069	I/II	Squamous cell carcinoma of head and neck	NCT02499328	Active, not recruiting
	I/II	PDAC	NCT02583477	Completed
	I/II	Metastatic castrate-resistant prostate cancer	NCT03177187	Terminated
BMS-986253	I/II	Hormone-sensitive prostate cancer	NCT03689699	Active, not recruiting
	I/II	HCC	NCT04050462	Active, not recruiting
	I	HCC, NSCLC	NCT04123379	Recruiting
	I/II	Metastatic or unresectable solid tumours	NCT03400332	Recruiting
	I	Metastatic solid tumours	NCT04572451	Recruiting
SX-682	I	Metastatic melanoma	NCT03161431	Recruiting
	I	PDAC	NCT04477343	Recruiting
	I	Myelodysplastic syndrome	NCT04245397	Recruiting
Navarixin/MK-7123	II	Advanced/metastatic solid tumors	NCT03473925	Completed
Reparixin	II	Breast cancer	NCT02370238	Completed
	I	Breast cancer	NCT02001974	Completed
C/EBPα
MTL-CEBPA small activating RNA	I	HCC	NCT02716012	Unknown status
	I	Solid tumors	NCT04105335	Active, not recruiting
TGF-β pathway inhibitors
Galunisertib	II	Glioblastoma	NCT01582269	Active, not recruiting
	I	Glioma	NCT01682187	Active, not recruiting
	I	Ovarian carcinosarcoma	NCT03206177	Unknown status
	I	Breast cancer	NCT02672475	Active, not recruiting
	II	Metastatic castration-resistant prostate cancer	NCT02452008	Recruiting
	II	Rectal cancer	NCT02688712	Active, not recruiting
	II	Nasopharyngeal carcinoma	NCT04605562	Not yet recruiting
	I	HCC	NCT02240433	Completed
	II	HCC	NCT01246986	Completed
	I/II	HCC, Solid tumors and NSCLC	NCT02423343	Completed
	I	PDAC	NCT02734160	Completed
Fresolimumab (GC1008)	I/II	NSCLC	NCT02581787	Completed
IMC-TR1	I	Neoplasms	NCT01646203	Completed
STAT3 inhibitors
Napabucasin	III	Colorectal cancer	NCT02753127	Completed
	I	HCC	NCT02358395	Completed
	I/II	HCC	NCT02279719	Completed
TTI101	I	HCC	NCT03195699	Active, not recruiting
Danvatirsen	I	HCC	NCT01839604	Completed
Lcaritin	I	HCC	NCT02496949	Completed
	II	HCC	NCT01972672	Completed
	III	HCC	NCT03236636	Unknown status
	III	HCC	NCT03236649	Terminated
TRAIL receptor 2 agonists
Tigatuzumab	II	Breast cancer	NCT01307891	Completed
	II	HCC	NCT01033240	Completed
CS-1008	I	Colorectal neoplasms	NCT01220999	Completed
DS8273a	I	Solid tumors and lymphoma	NCT02076451	Completed
	I	Colorectal cancer	NCT02991196	Terminated
	I	Melanoma	NCT02983006	Completed
CD47-SIRPα pathway inhibitors
Hu5F9-G4	I	Solid tumors	NCT02216409	Completed
IBI188	I	Advanced malignancies	NCT03717103	Completed
CC-90002	I	Hematologic neoplasms	NCT02367196	Completed
Magrolimab	I/II	Colorectal cancer	NCT02953782	Completed
TTI621	I	Solid tumors	NCT02890368	Terminated
AO176	I	Solid tumors	NCT03834948	Completed
BI765063	I	Solid tumors	NCT03990233	Active, not recruiting
Recombinant arginase 1/arginase 1 inhibitors
Pegzilarginase	I/II	Extensive disease small cell lung cancer	NCT03371979	Completed
INCB001158	I/II	Advanced/Metastatic solid tumors	NCT02903914	Completed
	I/II	Solid tumors	NCT03314935	Completed
Anti-C5aR
IPH5401	I	Advanced solid tumors	NCT03665129	Terminated
PDE5 inhibitors
Tadalafil	I	Liver dominant colorectal cancer or PDAC	NCT03785210	Completed
	II	Head and neck cancers	NCT02544880	Completed
Sildenafil	II/ III	NSCLC	NCT00752115	Completed
HDAC inhibitors
Resminostat	II	HCC	NCT00943449	Completed
Belinostat	I/II	HCC	NCT00321594	Completed
CCR5 inhibitor
Maraviroc	I	Colorectal cancer	NCT03274804	Completed
	I	Colorectal cancer	NCT01736813	Completed
CXCR4 inhibitor
Plerixafor	I	PDAC, colorectal and ovarian cancer	NCT02179970	Completed
NAMPT inhibitor
Daporinad	II	Cutaneous T cell lymphoma	NCT00431912	Completed
MMP9 inhibitor
Andecaliximab	III	Gastric adenocarcinoma	NCT02545504	Completed
NETs inhibitors
Pulmozyme (rhDNase)	I	Head and neck cancers	NCT00536952	Unknown status
Oshadi D	II	Acute myeloid/lymphoid leukemia	NCT02462265	Suspended

PDAC, pancreatic ductal adenocarcinoma; HCC, hepatocellular carcinoma; NSCLC, non-small cell lung cancer.